Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Comment by Pareto8020on Jan 04, 2024 11:03am
160 Views
Post# 35810477

RE:RE:RE:SBM real value

RE:RE:RE:SBM real valueWho knows since management doesn't disclose anything except that a deal was executed and it put a stupid smile on Howard's face.

Allergan has to incorporate SBM's compound into their product line and start selling it before Sirona gets any kind of royalty!  We are at a year and a half and nothing yet so any hope for their Botox killer to hit the shelves any year soon is far fetched based on historical timelines with SBM.

Im thinking 2024 is when Allergan's products with SBM's compound in them will finally hit the market but that is pure speculation on my part.  I see that being the only real catalyst in 2024 to jolt SBM out of the doldrums.  Unless they sign a Botox killer contract with details and timelines I don't see much else moving the needle.
<< Previous
Bullboard Posts
Next >>